The Treatment of Triple Negative Breast Cancer: Does Insurance Status Matter?
Hadadi, A.; Dale, P.; Fancher, C.; Lian, B.
American Surgeon 84(7): 259-261
2018
ISSN/ISBN: 0003-1348 PMID: 30064569 Document Number: 697199
Document emailed within 1 workday
Related Documents
Toh, U.; Saku, S.; Okabe, M.; Iwakuma, N.; Kimitsuki, Y.; Akashi, M.; Ogo, E.; Yamada, A.; Shichijo, S.; Itoh, K.; Akagi, Y. 2016: Development of Peptide Vaccines for Triple-Negative Breast Cancer Treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(10): 1249-1251Giuliani, S.; Leonardi, E.; Aldovini, D.; Bernardi, D.; Pellegrini, M.; Soli, F.; Ferro, A.; Dalla Palma, P.; Decarli, N.; Barbareschi, M. 2012: Frequency of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from Trentino, North East Italy Pathologica 104(3): 93-97
Fayaz, S.; Demian, G.A.; El-Sherify, M.; Eissa, H.; Aziz, M.; Abuzallouf, S. 2019: Triple Negative Breast Cancer: 10-Year Survival Update of The Applied Treatment Strategy in Kuwait Gulf Journal of Oncology 1(29): 53-59
Vincent-Salomon, A. 2013: Triple-negative breast cancer La Revue du Praticien 63(10): 1391-1392
Herold, C.I.; Anders, C.K. 2013: New targets for triple-negative breast cancer Oncology 27(9): 846-854
Zhang, M.; Zhou, Y.; Hu, Y.; Zhang, J. 2015: Effects of NVP-BKM120 on the triple-negative breast cancer cell Zhonghua Yi Xue Za Zhi 95(40): 3308-3312
Bilici, A.; Arslan, C.; Altundag, K. 2012: Promising therapeutic options in triple-negative breast cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 17(2): 209-222
Mel'nikov, D.I.; Pushina, I.V.; Lagereva, I.G.; Beĭkin, I.B.; Ivanova, I.I. 2013: Immunologic differences of triple-negative and luminal a breast cancer Voprosy Onkologii 59(3): 390-392
Mise, M.; Higashide, S.; Hashimoto, K.; Kawada, K.; Hanaki, K.; Kanda, Y.; Niikawa, Y.; Miyamoto, N.; Takeuchi, A.; Sawada, S.; Mikami, Y.; Noda, H. 2009: Clinicopathological features of young patients with triple negative breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(10): 1677-1681
Garber, J. 2017: Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer Oncology 31(11): 814
Sikov, W.M. 2017: Which patients with early-stage triple-negative breast cancer should receive a platinum? Clinical Advances in Hematology and Oncology: H&o 15(7): 510-514
2011: Categorization of triple-negative breast cancer patients will help in targeted therapy selection Oncology 25(9): 849
Collignon, J.; Struman, I.; Tabruyn, S.; Josse, C.; Boukerroucha, M.; Jerusalem, G.; Bours, V. 2011: Molecular and genetic aspects of triple negative breast cancer and therapeutic implications Revue Medicale de Liege 66(5-6): 393-396
Song, N.; Liang, B.; Wang, D. 2016: The function of MiR-21 expression differences and pathogenesis on familial and triple negative breast Cancer serum Pakistan Journal of Pharmaceutical Sciences 29(2 Suppl): 679-684
Miao, P-tian.; Tong, Z-sheng.; Hao, C-fang.; Zhang, L. 2010: Prognostic analysis of patients with metastatic triple-negative breast cancer: a report of 120 cases Zhonghua Yi Xue Za Zhi 90(40): 2848-2851
Gerson, R.; Alban, F.; Villalobos, A.; Serrano, A. 2008: Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype Gaceta Medica de Mexico 144(1): 27-34
Budakoglu, B.; Altundag, K.; Aksoy, S.; Kaplan, M.A.; Ozdemir, N.Y.; Berk, V.; Ozkan, M.; Algin, E.; Kandemir, N.; Dogu, G.G.; Harputluoglu, H.; Arslan, U.Y.; Coskun, U.; Isikdogan, A.; Oksuzoglu, B. 2014: Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey Journal of BUON: Official Journal of the Balkan Union of Oncology 19(4): 872-878
Riaz, A.; Rasul, A.; Hussain, G.; Zubair, M.; Samiullah, K.; Sarfraz, I.; Masood, M.; Jabeen, F.; Sultana, T.; Sultana, S. 2019: Eriocalyxin B induces apoptosis in human triple negative breast cancer cells via inhibiting STAT3 activation and mitochondrial dysfunction Pakistan Journal of Pharmaceutical Sciences 32(6 Supplary): 2843-2848
Chekhun, V.F.; Zhylchuk, V.E.; Lukyanova, N.Y.; Vorontsova, A.L.; Kudryavets, Y.I. 2009: Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients Experimental Oncology 31(2): 123-124
Halim, A.; Wahba, H. 2012: Cisplatin-ifosfamide combination chemotherapy in metastatic triple-negative, anthracycline- and taxane-pretreated breast cancer patients; a phase II study Journal of BUON: Official Journal of the Balkan Union of Oncology 17(2): 254-258